The middle fossa approach provides neurotologic surgical access to lesions of the geniculate ganglion and the labyrinthine portion of the facial nerve as well as to the internal acoustic canal, and therefore helps preserve cochlearfunction . Although this approach is widely used, surgeons are still not certain which anatomic landmarks are best to locate the facial nerve and internal acoustic canal without causing labyrinthine damage . The purpose of this article is to describe a fast and safe technique to expose the geniculate ganglion and the labyrinthine portion ofthefacial nerve in two structures ofthe middle ear: the cochleariform process and the tympanic portion ofthe facial nerve. We prospectively evaluated 32 patients who underwent surgicalfacial nerve exploration via the middle fossa approach. Our goal was to determine the inciden ce ofintraoperative difficulties and complications; wefound none, and hearing levels could not be maintained in only one of the 32 patients. Our technique allowed us to decompress the first genu and the labyrinthine segment of the nerve. It also allowed us to reach and manipulate its tympanic segment in a velY short amount ofsurgical time.
Introduction
The middle fossa approach was first used during the latter part of the 19 th century as a means of exposing the trigeminal ganglion. In 1961, House became the first to report the use of this approach for the removal of an acoustic neuroma.' Five years later , Pulec was the first to describe the use of this technique for total facial nerve From the Dep artment of Otolar yngology , University of Sao Paulo , Brazil. Reprint reque sts: Ricardo Ferreira Bento, MD, Rua Pedro so Alvaren ga 1255 cj. 22, 04531-012, Sao Paulo, Brazil. Phone: +55-11-3167-6556; fax: +55-11-3812-9129; e-mail: rbento @attglobal.net 320 decompression.' Today, the middle fossa approach is used worldwide, primarily to access tumors in the internal auditory canal that have only a slight protrusion into the cerebellopontine angle. The middle fossa approach is used in patients who have useful hearing and to access the labyrinthine portion of the facial nerve in patients who have normal or near-normal hearing. r" The geniculate ganglion and the labyrinthine segment of the facial nerve can be reached via both the middle fossa approach and the transmastoid approach." Both approaches have their surgical limitations, and it is important that surgeons be comfortable with both. One advantage of the transmastoid approach to the geniculate ganglion is that craniotomy is not necessary. However, in a poorly pneumatized temporal bone, it is not possible to reach the geniculate ganglion and the labyrinthine segment of the fac ial nerve with this approach. Also, the trans mastoid approach exposes the entire labyrinthine segment of the facial nerve in only 60% of patients, mainly via the superior semicircular canal .v'
The middle fossa approach provides a safe and direct route to the meatal, geniculate, and labyrinthine segments ofthe facial nerve. It has been used as a first-line approach in facial nerve surgery by most neurotologists because it allows for uniform visualization of and access to the facial nerve with minimal risk to the labyrinth. The two major concerns with this route are (1) the need for a wide temporal lobe retraction to permit a broad view of the anterior surface of the petrous pyramid and (2) the difficulty in finding anatomic landmarks that allow for the correct identification of and access to the internal acoustic canal and the fallopian channel without damaging the labyrinth. The distance from the labyrinthine portion of the facial nerve to the cochlea ranges from 0.5 to 1.0 mm, although early reports estimated that this distance might • Powerful SAR symptom relief all day and all night long with 180 mg qd-even at trough levels! • The ONLY 2nd-generation antihistamine that's proven to be nonsedating even at more than twice the recommended qd dose" * • Does not impair driving-patients on Allegro 60 mg performed similarly to patients on placebo in a computerized driving simulator study"
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Bridgewater , NJ 08807 A RAPID AND SAFE MIDDLE FOSSA APPROACH TO THE GENICULATE GANGLION AND LABYRINTHINE SEGMENT OF THE FACIAL NERVE be much shorter in as many as 75% of patients. " Although extradural temporal lobe retraction today is safe and carries a minimal risk of injury to the temporal lobe, surgeons are still not certain which anatomic landmarks are best to locate the facial nerve and internal acoustic canal without causing labyrinthine damage."
Because there are almost no topographic landmarks along the floor of the middle cranial fossa, orientation to the underlying structures can be a challenge. Several methods are available for localizing the internal acoustic canal and the facial nerve in the middle fossa floor:
• The Fisch method is based on identifying the arcuate eminence. The arcuate eminence is the major landmark used to safely locate the internal acoustic canal and its contents, which are often located at a 60°angle to the bluelined superior semicircular canal. 10 • The Pulec method involves tracing the greater superficial petrosal nerve to the geniculate ganglion and then exposing the labyrinthine segment of the facial nerve and the internal acoustic canal. II • Jackler drilled a deep trough into the apical petrous bone anterior to the anticipated location of the canal.'? Then, using the side of a diamond bur, he was able to delineate the anterior margin of the canal's dura and the porus acusticus internus.
• Garcia-Ibanez and Garcia-Ibanez proposed using the bisection of the angle formed by imaginary lines that pass through the greater superficial petrosal nerve and the arcuate eminence."
• Sterkers' technique is based on identifying the internal acoustic canal by drilling bone 28 mm medial to the squama on the biauricular line.14 • Catalano and Eden reported using the head of the malleus and the lateral cortex of the temporal squama at the zygoma root as external references to identify the internal auditory canal. 15 We have routinely used the middle fossa approach to decompress the facial nerve and to remove small facial nerve tumors . In this article, we describe a fast method used in our service to access the geniculate ganglion and the labyrinthine portion of the facial nerve. five had had a small meningioma, and two had had a facial nerve schwannoma.
Patients and methods
During middle fossa surgery, each patient was placed in the supine position with the head rotated to one side. The surgeon sat at the head of the operating table. The skin incision began at the edge of the zygoma root and extended superiorly for approximately 7 em (figure I). After the temporal muscle flap was retracted, a craniotomy was made by opening a 3 x 4-cm rectangular bone flap (figure 2). The elevation of the dura allowed for the visualization of the greater superficial petrosal nerve anteriorly, the arcuate eminence, the superior semicircu-
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Otolaryng larcanal, and the roof ofthe middle ear ( figure 3) .The roof of the middle ear was easily identified by its dark color. The surgeon opened a small hole with a diamond bur and identified the cochleariform process and the adjacent segment of the facial nerve ( figure 4) . The facial nerve was then followed until the geniculate ganglion could be visuali zed ( figure 4 ). Once the geniculate ganglion was identifi ed, the labyrinthine segment was easily exposed (figure 4).
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Results
In this prospective series, we based our findings on three parameters: (1) the incidence of intraoperative difficulties or complications, (2) the incidence of immediate (~1 mo) postope rative complications, and (3) the result s of audiolo gic evaluations 90 days postoperatively.
Intraoperative difficulties. We did not experience any intraoperative difficulties or compl ications. A udiologic testing. Our eva luat ion of patients 90 days afte r surgery found only one case of anacusis. Thi s patient had a small facia l nerve schwannoma at the first genu, and the patient's cochlea had been opene d during tum or removal. No change in posto per ative hearing was detecte d in any other patient. We also found another positive aspect to the middle fossa approac h; there was no need for a wide retraction of the temporal lobe to locate the tegme n tympani. We used the described technique for all 32 middle fossa operations. We did not have any difficulty finding and opening the tegmen tympani. The malleus and the cochlearifor m process were identified without difficulty, and no manipulation of the ossicul ar chain was needed to obt ain a direct view of the second portion of the facial nerve. The next step was to reach the geniculate ganglion by foll owing the tymp anic seg ment of the facial nerve. After the Volume 81, Number 5
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Call or email for fr ee samples. Figure 4 . A : After the tegmen tympani is opened with a small diamond bur, the cochleariform process (CP) and the tympanic segment (TS) of the facial nerve are identifiable. B: The fa cial nerve is thenfollowed until the geniculate ganglion (GG) can be visualized. C: Once the geniculate ganglion is identified, the labyrinthine segment (LS) is easily exposed and decompressed (AE = arcuate eminence).
geniculate ganglion was expose d, the labyrinthine segment was easily reached. This access allowed the surgeo n to decompress the first genu and the labyrinthine segment of the nerve and to reach and manipulate its tympanic segment.
Discussion
The arcuate eminence is the major landmark used to 324 safely locate the internal acoustic canal, which is often located at a 60°angle to the blue-lined superior semicircular canal.10Thi s is the most common way of finding the internal acoustic canal and the labyrinthi ne segment of the facial nerve. However, there are some problem s with this method. In about 15% of temporal bones, the arcuate eminence is not identifiable because it is located posterior to the superior semicircular canal rather than directl y over it. As a result, this method relies on a landm ark whose location is not invariable because its position can be altered by the amount of temporal bone pneumatization. 16 Another option is to locate the geniculate ganglion by exposing the greater superfici al petrosal nerve . However, this approach requires a wide tempor al lobe retraction, which carries the risk of bleeding from the veins around the foramen spinosum. By exposing the greater superficial petrosal nerve up to the geniculate ganglion, this techniqu e carries the risk of causing a lesion in the petrosal artery. The petrosal artery runs parallel to the greater superficial petrosal nerve and supplies the facial nerve at the area of its first genu and the labyrinth ine segment. The bleedin g caused by a lesion in this artery could result in a difficult surgery and possible compromise of the facial nerve blood supply. Most of the techniques that are useful in reaching the interna l acoustic canal are not usually performed when the facial nerve is the only structure to be exposed.":"
To avoid the difficulti es encountered with other techniques, we use the cochleariform process in the middle ear as the prim ary landm ark for identifying the tympani c segment of the facial nerve. We then follow this segment to reach the geniculate ganglion and the labyrinthine segment. The cochleariform process is easily found in the middle fossa appro ach by opening a small hole (0.5 em) in the tegmen tymp ani. The second portion of the facial nerve can then be identifi ed ju st adjacent to the cochle ariform process, and it can be followed to the geniculate ganglion. Thi s technique is safe and allows the surgeon to quickly decompress the first segment and the first genu. This strategy also makes it possible to reach the tympanic segment of the nerve. This is interesting because even when our goal is ju st to decompress the labyrinth ine segment, as we do for Bell' s palsy, it is possible for us to perform an amplified decompression, one that includ es part of the second segment, without needing to perform a mastoidectomy.
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We concl ude that the cochlearifor m process and the tympanic segment of the facia l nerve can be routinely used as landmarks for the safe exploration of the labyrinthine segment of the facial nerve in the middle fossa approach.
